Group 1 - Xinjiang Tianye (SH 600075) announced on October 24 that its ninth board meeting was held via communication voting, discussing the proposal to supplement the daily related transaction limit for 2025 [1] - For the year 2024, Xinjiang Tianye's revenue composition is as follows: industrial sector accounts for 93.96%, commercial sector for 3.34%, other businesses for 1.78%, and transportation for 0.92% [1] - As of the report, Xinjiang Tianye has a market capitalization of 8 billion yuan [1] Group 2 - The Chinese innovative drug sector has sold overseas authorizations worth 80 billion USD this year [1] - There is a contrast in the biopharmaceutical secondary market being active while the primary market is facing fundraising challenges [1]